Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated

Mirko Tarocchi1, Rebekka Hannivoort, Yujin Hoshida

  • 1Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029-6574, USA.

Abstract

Insights

Kruppel-like factor 6 (KLF6) deficiency promotes liver cancer (HCC) by increasing MDM2, which destabilizes the tumor suppressor p53. Restoring KLF6 function could be a therapeutic strategy for HCC.

Area of Science:

  • Hepatocellular carcinoma (HCC) research
  • Cancer biology
  • Molecular oncology

Background:

  • Kruppel-like factor 6 (KLF6) inactivation is frequent in hepatitis C virus-associated hepatocellular carcinoma (HCC).
  • KLF6 normally functions as an antiproliferative factor in liver cells.
  • The role of KLF6 in hepatocarcinogenesis requires further elucidation.

Purpose of the Study:

  • To investigate the impact of KLF6 depletion on human HCC and experimental liver cancer.
  • To determine the molecular mechanisms underlying KLF6's tumor suppressor activity in HCC.

Main Methods:

  • Analysis of KLF6 expression in human HCC tumors and patient survival data.
  • In vivo studies using KLF6+/- mice treated with diethyl nitrosamine (DEN).
  • Gene expression profiling, quantitative real-time PCR, Western blot, chromatin immunoprecipitation, and cotransfection assays.

Main Results:

  • Reduced KLF6 expression in human HCC correlates with decreased patient survival.
  • KLF6+/- mice exhibit increased tumor formation and HCC signatures similar to aggressive human tumors.
  • KLF6 deficiency leads to increased MDM2 mRNA and protein levels, consequently reducing p53 stability and activity.

Conclusions:

  • KLF6 deficiency significantly contributes to the carcinogenic environment in both human and murine HCC.
  • KLF6 acts as a tumor suppressor in HCC by transcriptionally repressing MDM2, thereby stabilizing p53.